| Old Articles: <Older 6431-6440 Newer> |
|---|
 |
The Motley Fool
June 29, 2010
Brian Orelli |
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.   |
HBS Working Knowledge
June 28, 2010
Julia Hanna |
HBS Cases: Cincinnati Children's Hospital Medical Center This case explores how one hospital implemented its own version of health-care reform, taking overall performance levels from below average to the top 10 percent in the industry. |
The Motley Fool
June 28, 2010
Brian Orelli |
The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
The Motley Fool
June 25, 2010
Brian Orelli |
Diversification Times 50,000 Gilead Sciences diversifies any way it can. |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
June 25, 2010
Brian Orelli |
Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
| <Older 6431-6440 Newer> Return to current articles. |
